Market reaction and regulatory action
Shares of Unicycive Therapeutics Inc. (NASDAQ: UNCY) tumbled 37% on Tuesday following receipt of a Complete Response Letter (CRL) from the U.S. Food and Drug Administration related to the company's resubmitted New Drug Application for oxylanthanum carbonate. The CRL identified deficiencies at a third-party manufacturing vendor - the same deficiencies that were noted in an earlier Complete Response Letter issued in June 2025.
Manufacturing issues at the center
The FDA cited shortcomings at the external manufacturing facility as the basis for the CRL. According to the correspondence, the agency did not perform an inspection of that third-party site during its review of the resubmitted application.
Clinical package left intact
Importantly, the FDA did not express concerns about the clinical efficacy or safety data supporting oxylanthanum carbonate. No additional clinical or safety studies were requested by the agency in the communication, and the company was not asked to supply new clinical datasets.
Indication and supporting evidence
Oxylanthanum carbonate is being developed for treatment of hyperphosphatemia in patients with chronic kidney disease receiving dialysis. The NDA includes data from three clinical investigations: a Phase 1 trial in healthy volunteers, a bioequivalence study in healthy volunteers, and a tolerability study conducted in chronic kidney disease patients on dialysis. The submission is also supported by preclinical studies and chemistry, manufacturing and controls (CMC) documentation.
Company expectations and regulatory interactions
Unicycive resubmitted the NDA on the basis that the original third-party manufacturing vendor had made continued progress addressing the FDA-cited deficiencies. The company had previously discussed these remediation milestones with the FDA during a Type A meeting in September 2025. Separately, Unicycive reported it is engaged in active discussions with the agency concerning labeling and packaging matters, noting the most recent interaction on June 29 focused on carton and container labels.
Near-term implications and next steps
The CRL centers on manufacturing-related deficiencies at an external vendor rather than the clinical dataset or safety profile of the candidate drug. The company's ongoing dialogue with the FDA on labeling and packaging remains active, but the unresolved issues at the third-party facility form the current obstacle to approval.
Note: This report summarizes the regulatory developments and market response as communicated by the company and the FDA correspondence. It presents the materials and interactions described without additional inference.